Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 10, 2025
Daily News
April 10, 2025
- Clinical Trial Matching Websites Do Not Violate Ad Regulations in PMD Act: MHLW
April 10, 2025
- MHLW Sets Up Task Force to Brace for US Tariffs
April 10, 2025
- Repeal of Off-Year Revision Means No Price Raise for Unprofitable Drugs: Minister
April 10, 2025
- Bill to Nix Off-Year Scheme Politicized, Could Clear Lower House with Ishin Support
April 10, 2025
- Kaken Bags Japan Commercial Rights to KalVista’s HAE Drug
April 10, 2025
- Chuikyo OKs Discussion Timeline for FY2026 Reimbursement Reform
April 10, 2025
- Amgen’s Imdelltra, CSL’s Andembry to Join NHI Price List on April 16
April 10, 2025
- Contradictions in Drug Pricing System Can No Longer Be Overlooked: Ex-Bureaucrat
April 10, 2025
- Pivot Away from Social Security Spending Cap: Labor Union to Govt
April 10, 2025
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…